Next Case Study

Label extension

In silico clinical trial to support label extension.


The Sponsor has considered the request of a label extension for a drug which is currently used off-label in MS patients.

Question of Interest

Could modeling and simulation provide evidence that off-label administration delays disease progression without impacting safety parameters? 


An in silico clinical trial was conducted using an agent-based model of innate and adaptive immune system as well as MS disease progression.


Simulations confirmed the efficacy and safety of the off-label administration in virtual MS patients.    


  •  The Sponsor included the in silico evidence into the dossier requesting label extension to regulatory body.
  • The Sponsor intends to publish the analysis results in a peer-reviewed journal.

Related Case Studies

In silico QSTR Model

In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.

Read More »

Fill the details to download the case study

Download your case study by clicking the link below